A Limitless Pipeline

We Have a Diverse and Broad Portfolio.

Plexium’s Pipeline is rich and diverse, driven by its differentiated platform that supports the discovery of diverse molecular glues and monovalent protein degraders.

Our advanced stage projects include molecular glues that selectively degrade the undruggable IKZF2 transcription factor, and selective monovalent degraders of the clinically validated epigenetic regulator BRD4. We are also targeting selective degraders of therapeutically important proteins such as CDK2 and SMARCA2, as well as exploring molecular glues based on novel E3 ligases.

With a robust wholly owned pipeline, complemented by a comprehensive set of partnered programs, Plexium is leading the way to seeking new opportunities in the exciting Targeted Protein Degradation space.

The possibilities for a robust pipeline are limitless, and this is just the beginning.